Differences in overall survival between clear cell metastatic renal cell carcinoma patients versus population-based controls according to race/ethnicity in the United States.

PURPOSE To quantify differences in five-year overall survival (OS) between clear cell metastatic renal cell carcinoma (ccmRCC) patients and age- and sex-matched population-based controls, especially when race/ethnicity is considered. METHODS We relied on the Surveillance, Epidemiology and End Results database (2006-2016) to identify newly diagnosed (2006- 2011) ccmRCC patients of either Caucasian, Hispanic, African American or Asian/Pacific Islander race/ethnicity. For each case, we simulated an age- and sex-matched control (Monte Carlo simulation), relying on Social Security Administration Life Tables with five-year follow-up. We compared OS between ccmRCC patients and controls. Multivariable Cox regression models tested for race/ethnicity effect on OS. RESULTS Of 3067 ccmRCC patients, 2167 (71%) were Caucasians vs. 488 (16%) Hispanics vs. 216 (7%) African Americans and 196 (6%) Asians/Pacific Islanders. At five years, OS difference between ccmRCC patients vs. population-based controls was greatest in African Americans (11 vs. 94%, Δ=84%), followed by Hispanics (16 vs. 94%, Δ=77%), Caucasians (16 vs. 89%, Δ= 73%) and Asians/Pacific Islanders (19 vs. 88%, Δ=70%). In multivariable Cox regression models, African Americans exhibited highest Hazard Ratio for death (HR 1.3, p=0.003). CONCLUSION Relative to Life Tables' derived age- and sex-matched controls, ccmRCC patients exhibit drastically worse OS, especially African Americans.

[1]  F. Saad,et al.  Life expectancy in metastatic urothelial bladder cancer patients according to race/ethnicity , 2022, International Urology and Nephrology.

[2]  M. Graefen,et al.  Long‐term overall survival of radical prostatectomy patients is often superior to the general population: A comparison using life‐table data , 2021, The Prostate.

[3]  F. Saad,et al.  Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups , 2021, International journal of urology : official journal of the Japanese Urological Association.

[4]  R. Motzer,et al.  Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. , 2020, Cancer.

[5]  R. Motzer,et al.  Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  F. Saad,et al.  Racial and ethnic differences in survival in contemporary metastatic renal cell carcinoma patients, according to alternative treatment modalities , 2020, Cancer Causes and Control.

[7]  R. Motzer,et al.  Towards individualized therapy for metastatic renal cell carcinoma , 2019, Nature Reviews Clinical Oncology.

[8]  R. Motzer,et al.  Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions. , 2019, European urology.

[9]  F. Saad,et al.  Validation of the Social Security Administration Life Tables (2004-2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database. , 2019, European urology focus.

[10]  P. Humphrey,et al.  The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. , 2016, European urology.

[11]  P. Kantoff,et al.  Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[12]  J. Gore,et al.  Trends in Metastatic Kidney Cancer Survival From the Cytokine to the Targeted Therapy Era. , 2015, Urology.

[13]  K. Schwartz,et al.  The effect of targeted therapy on overall survival in advanced renal cancer: a study of the national surveillance epidemiology and end results registry database. , 2014, Clinical genitourinary cancer.

[14]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.